| Name | Carbazochrome sodium sulfonate |
| Description | Carbazochrome sodium sulfonate (AC-17) is an antihemorrhagic agent used for treating hemorrhoids. |
| In vitro | Administering 10 mg/kg of Carbazochrome significantly inhibited the reduction of arterial oxygen levels. Additionally, at the same dosage, Carbazochrome reversed the iodocetate-induced increase in vascular permeability in rats in a dose-dependent manner. |
| In vivo | Carbazochrome at concentrations of 0.1-1 M attenuates concentration-dependent synthesis of [(3)H]myo-inositol and [(3)H]-inositol induced by bradykinin and thrombin. It also counteracts the functional impairment caused by trypsin, thrombin, and bradykinin, with ionophores like ionomycin, A23187, or phorbol 12-myristate 13-acetate enhancing this effect without affecting endothelial permeability. In human umbilical vein endothelial cells, carbazochrome significantly reduces the ratio of t-PA antigen in the culture medium without notably affecting the PAI-1 antigen ratio. It reverses trypsin-induced actin stress fiber formation and disrupts VE-cadherin in monolayers of porcine aortic endothelial cells. Additionally, in cultured bovine vascular endothelial cells, carbazochrome distinctly inhibits hyperpermeability induced by trypsin, thrombin, and protease-activated receptor 2 agonist peptides. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | Ethanol : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 12 mg/mL (37.26 mM), Sonication is recommended.
H2O : 3 mg/mL (9.3 mM)
|
| Keywords | stabiliser | inhibit | capillary | Inhibitor | AC17 | antihemorrhagic | AC 17 | Carbazochrome sodium sulfonate | haemorrhage |
| Inhibitors Related | Olanzapine | Mirtazapine | Octopamine hydrochloride | Gemfibrozil | Dexmedetomidine hydrochloride | Phenylephrine hydrochloride | Isoprenaline hydrochloride | Amitriptyline hydrochloride | Trazodone hydrochloride | Mianserin hydrochloride |
| Related Compound Libraries | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Anti-Alzheimer's Disease Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
United States
